Search results for "antidepressive agents"

showing 10 items of 191 documents

Clinical responses to antidepressants among 1036 acutely depressed patients with bipolar or unipolar major affective disorders.

2012

Whether responses to antidepressants differ in bipolar and unipolar depression remains unresolved.We analyzed patient characteristics and outcomes of antidepressant treatment of 1036 depressed patients with bipolar-I or bipolar-II disorder, or unipolar major depression, using bivariate and multivariate methods and survival analysis, testing the hypothesis that responses would be superior in unipolar depression.Antidepressants were given to 84.8% (878/1036) of depressed patients: 58.9% of 93 bipolar-I, 80.1% of 117 bipolar-II, and 91.3% of 668 unipolar disorder cases. The 158 not given antidepressants had more manias/year, spent more months in mania and depression, and were far more likely t…

AdultMalemedicine.medical_specialtyBipolar DisorderMonoamine Oxidase InhibitorsAntidepressive Agents Tricyclicbehavioral disciplines and activitiesInternal medicinemental disordersmedicineHumansBipolar disorderPsychiatrySurvival analysisDepression (differential diagnoses)Depressive Disorder MajorManic MoodMiddle Agedmedicine.diseaseAntidepressive AgentsPsychiatry and Mental healthMoodTreatment OutcomeMajor depressive disorderAntidepressantFemalemedicine.symptomPsychologyManiaSelective Serotonin Reuptake InhibitorsActa psychiatrica Scandinavica
researchProduct

CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine.

2006

SUMMARY Background: Venlafaxine (V) is a mixed serotoninand noradrenaline reuptake inhibitor used as afirst-line treatment of depressive disorders. It ismetabolized primarily by the highly polymorphiccytochrome P450 (CYP) enzyme CYP2D6 to yielda pharmacologically active metabolite, O-des-methylvenlafaxine (ODV), and to a lesser extentby CYP3A4, to yield N-desmethylvenlafaxine(NDV).Objectives: The aim of this study was to assesswhether the O-demethylation phenotype of V hasan impact on the pharmacokinetics and clinicaloutcome.Method: In 100 patients treated with V, serumconcentrations of V, ODV and NDV and theratios of concentrations ODV/V as a measure ofO-demethylation were determined. Indiv…

AdultMalemedicine.medical_specialtyCYP2D6AdolescentGenotypeVenlafaxine HydrochlorideVenlafaxineBiology030226 pharmacology & pharmacy03 medical and health sciences0302 clinical medicinePharmacokineticsInternal medicineDesvenlafaxine SuccinateGenotypemedicineHumansPharmacology (medical)Active metaboliteAgedPharmacologyDepressive DisorderPolymorphism GeneticfungiVenlafaxine HydrochlorideMiddle AgedCyclohexanols3. Good healthEndocrinologyCytochrome P-450 CYP2D6PharmacogeneticsAntidepressive Agents Second-GenerationFemaleReuptake inhibitor030217 neurology & neurosurgeryPharmacogeneticsmedicine.drugJournal of clinical pharmacy and therapeutics
researchProduct

A combined marker of early non-improvement and the occurrence of melancholic features improve the treatment prediction in patients with Major Depress…

2017

Abstract Background Early Improvement of depressive symptoms within two weeks of antidepressant treatment is a highly sensitive but less specific predictor of later treatment outcome. The aim of this study was to identify clinical features at treatment initiation which are associated with early improvement and non-improvement as well as to identify variables predicting non-remission in patients showing an early improvement. Methods 889 patients with a major depressive episode according to DSM-IV who had participated in an antidepressant treatment trial served as study sample. Clinical predictors (demographic variables, psychopathology, comorbid disorders) were analysed in 698 (79%) early im…

AdultMalemedicine.medical_specialtyComorbidityAvoidant personality disorderPatient ReadmissionSeverity of Illness IndexSuicidal Ideation03 medical and health sciences0302 clinical medicineRisk FactorsRating scaleInternal medicinemedicineHumansMajor depressive episodePsychiatryAtypical depressionDepression (differential diagnoses)Depressive Disorder Majorbusiness.industryMiddle Agedmedicine.diseaseAntidepressive Agents030227 psychiatryPsychiatry and Mental healthClinical PsychologyTreatment OutcomeMajor depressive disorderAntidepressantFemalemedicine.symptombusiness030217 neurology & neurosurgeryPsychopathologyJournal of Affective Disorders
researchProduct

Body mass index (BMI) in major depressive disorder and its effects on depressive symptomatology and antidepressant response

2019

Obesity is one of the most prevalent somatic comorbidities of Major Depressive Disorder (MDD). We aimed to investigate the relationship between body mass index (BMI) and MDD, the symptomatology of the disorder as well as the outcome of antidepressant treatment.Early medication change (EMC) trial participants with BMI measurement (n = 811) were categorized according to WHO-criteria in normal or low weight (BMI  25), overweight (25- 30), and obese (≥30). Depression severity and BMI was assessed in weekly intervals up to 8 weeks. BMI at baseline and course of BMI during the study were investigated in linear regression models as possible moderators of therapy response. Possible moderators such …

AdultMalemedicine.medical_specialtyComorbidityOverweightWeight GainBody Mass IndexDepressive symptomatology03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansObesityDepression (differential diagnoses)Depressive Disorder Majorbusiness.industryMiddle Agedmedicine.diseaseObesityAntidepressive Agents030227 psychiatryPsychiatry and Mental healthClinical PsychologyAntidepressantMajor depressive disorderFemalemedicine.symptombusinessWeight gainBody mass index030217 neurology & neurosurgeryJournal of Affective Disorders
researchProduct

Serum Concentrations of Fluvoxamine and Clinical Effects: A prospective open clinical trial

1998

This pilot study examined prospectively blood serum concentrations of fluvoxamine, side effects and therapeutic response after a fixed dosage of 100 mg fluvoxamine/day for 14 days. Twenty male and female patients who met the DSM-IV criteria of a major depression received 50 mg fluvoxamine b.i.d. for two weeks. On days 7 and 14 side effects and therapeutic response were registered and serum concentrations of fluvoxamine were determined. A Receiver Operating Characteristic (ROC) curve was constructed to determine a possible relationship between serum concentrations and clinical effects. The serum concentrations of fluvoxamine were highly variable, even when dosages were corrected for body wei…

AdultMalemedicine.medical_specialtyDosemedicine.medical_treatmentFluvoxamineGastroenterologyBlood serumInternal medicinemedicineHumansPharmacology (medical)Prospective StudiesAgedAged 80 and overDepressive DisorderChemotherapymedicine.diagnostic_testReceiver operating characteristicbusiness.industryGeneral MedicineMiddle AgedClinical trialPsychiatry and Mental healthROC CurveFluvoxamineTherapeutic drug monitoringAnesthesiaAntidepressive Agents Second-GenerationFemaleDrug MonitoringbusinessReuptake inhibitormedicine.drugPharmacopsychiatry
researchProduct

Impact of the WHO depression guideline on patient care by psychiatrists: a randomized controlled trial.

2008

AbstractBackgroundScientific literature reviews aim to summarize the state of knowledge and published empirical evidence. In contrast, medical guidelines are intervention tools that aim to improve physician behaviour and patient outcome. They can have positive effects, but they can also have negative effects. Their effects must be tested by research.MethodsIn a randomized controlled trial, 103 psychiatrists in private practice were either provided with the WHO depression guideline only (information group), or provided with the WHO depression guideline and trained for one day in this guideline (intervention group), or left uninformed (control group). They then treated a total of 497 patients…

AdultMalemedicine.medical_specialtyEvidence-based practiceInservice TrainingMirtazapineMianserinAntidepressive Agents TricyclicWorld Health Organizationlaw.invention03 medical and health sciences0302 clinical medicineContinuing medical educationRandomized controlled triallawGermanymedicineHumans030212 general & internal medicinePsychiatryAgedPsychiatryDepressive Disorderbusiness.industryEvidence-based medicineGuidelineMiddle AgedMental health030227 psychiatryPsychiatry and Mental healthAffectPrivate practicePractice Guidelines as TopicPhysical therapyFemalebusinessPsychosocialEuropean psychiatry : the journal of the Association of European Psychiatrists
researchProduct

State dependent posterior hippocampal volume increases in patients with major depressive disorder.

2011

Abstract Background The hippocampal formation has been implicated in etiology and therapy response in major depressive disorder (MDD). However, prospective longitudinal studies investigating volumes in hippocampal subregions and their association with clinical findings are still lacking. Methods Global and regional hippocampal volumes and neuropsychological performance were assessed longitudinally in 15 young patients with unipolar early onset MDD who responded to therapy and 13 matched healthy control subjects. Results Although volumes at baseline did not differ between groups, patients with MDD showed significant posterior hippocampal volume increases during the treatment course (mean obs…

AdultMalemedicine.medical_specialtyHippocampusHippocampal formationNeuropsychological TestsHippocampusYoung AdultInternal medicineNeuroplasticitymedicineHumansLongitudinal StudiesProspective StudiesDepressive Disorder MajorNeuronal PlasticityNeuropsychologyOrgan SizeMiddle Agedmedicine.diseaseMagnetic Resonance ImagingAntidepressive AgentsPsychiatry and Mental healthClinical PsychologyCase-Control StudiesEtiologyCardiologyHippocampal volumeAntidepressantMajor depressive disorderFemalePsychologyNeuroscienceJournal of affective disorders
researchProduct

Differential effects of the enantiomers R(-) and S(+) oxaprotiline on major endogenous depression, the sleep EEG and neuroendocrine secretion: studie…

1993

The effects of the optically active enantiomers of oxaprotiline (OXP), R(-) OXP and S(+) OXP, on depressive symptomatology and the sleep EEG were investigated in two separate exploratory studies. In addition, the neuroendocrine profile of both compounds was characterized in normal controls. In the patients treated with a daily oral dose of 150 mg S(+) OXP we found a Hamilton depression score that decreased from 29.1 +/- 1.8 (SEM) on day 0 to 14.7 +/- 3.2 on day 28 (P0.01). Six patients were judged to be full responders (HAMD score 0-7 points), three were improved (HAMD score 8-15) and four were nonresponders (HAMD score16). The therapeutic effect achieved with 150 mg R(-) OXP daily was less…

AdultMalemedicine.medical_specialtyHydrocortisoneSleep REMchemistry.chemical_compoundNorepinephrineInternal medicineHamdmedicineHumansPharmacology (medical)SecretionTestosteroneBiological PsychiatryTestosteroneAgedPharmacologyPsychiatric Status Rating ScalesDepressive DisorderNeurosecretionPenile ErectionTherapeutic effectOxaprotilineElectroencephalographyStereoisomerismMiddle AgedProlactinAntidepressive AgentsProlactinPsychiatry and Mental healthEndocrinologyNeurologychemistryMaprotilineGrowth HormoneEndogenous depressionFemaleNeurology (clinical)EnantiomerPsychologySleepEuropean neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
researchProduct

Multisteroid analysis after DST in depressed patients — A controlled study

1986

Abstract 111 consecutively admitted in-patients with a depressive syndrome received a dexamethasone suppresion test (DST) after all known factors which might confound the test results had been carefully excluded. Plasma concentrations of cortisol, corticosterone and dexamethasone were compared with several diagnostic evaluations (RDC, DSM-III, ICD-9) in a controlled study. The positive predictive value of nonsuppressed corticosteroid levels was only moderate for each diagnostic category. Diagnostic specificities were 84.6% for major depression, endogenous subtype (RDC), 71.2% for melancholia (DSM-III) and 86.8% for endogenous depression (IDC-9) when using a post-DST cortisol value above 50 …

AdultMalemedicine.medical_specialtyHydrocortisonemedicine.drug_classDexamethasonechemistry.chemical_compoundCorticosteroneInternal medicineMelancholiamedicineHumansDepression (differential diagnoses)DexamethasoneAgedDepressive DisorderMiddle AgedAntidepressive AgentsPsychiatry and Mental healthClinical PsychologyEndocrinologychemistryDexamethasone suppression testEndogenous depressionCorticosteroidFemaleMajor Diagnostic Categorymedicine.symptomCorticosteronePsychologymedicine.drugJournal of Affective Disorders
researchProduct

Quality of life and subjective well-being in schizophrenia and schizophrenia spectrum disorders : Valid predictors of symptomatic response and remiss…

2010

To examine quality of life and subjective well-being as predictors of symptomatic treatment outcome.Biweekly PANSS ratings were performed in 285 inpatients with schizophrenia spectrum disorders within a multicenter trial by the German Research Network on Schizophrenia. Quality of life and subjective well-being were assessed using the Medical Outcomes Study-Short Form 36-Item Health Survey (SF-36), the Subjective Well-being Under Neuroleptic Treatment Scale (SWN-K) and the Adjective Mood Scale (AMS). Response was defined as an initial 20% PANSS total score reduction and remission according to the consensus criteria. Correlation analysis, logistic regression and CART-analysis were performed.I…

AdultMalemedicine.medical_specialtyMedizinLogistic regressionMood scale03 medical and health sciencesYoung Adult0302 clinical medicineQuality of lifeMulticenter trialInternal medicinemedicineHumansSubjective well-beingBiological PsychiatryPsychiatric Status Rating ScalesMiddle Agedmedicine.diseasePrognosisAntidepressive Agents3. Good health030227 psychiatryHospitalizationPsychiatry and Mental healthTranquilizing AgentsPsychotic DisordersSchizophreniaCorrelation analysisQuality of LifeSchizophreniaDrug Therapy CombinationFemaleSchizophrenic PsychologyPsychology030217 neurology & neurosurgerySchizophrenia spectrumClinical psychologyAntipsychotic Agents
researchProduct